@article{TAU9665,
author = {Weiliang Chong and Ronny Ban Wei Tan},
title = {Injectable therapy for Peyronie’s disease},
journal = {Translational Andrology and Urology},
volume = {5},
number = {3},
year = {2016},
keywords = {},
abstract = {Peyronie’s disease is a disfiguring and psychologically devastating disease, which continues to pose a significant clinical conundrum to the attending doctor. Many forms of therapy have been trialled but results have been inconsistent at best. Non-surgical therapy revolves around oral, intralesional and shockwave therapies. The focus of this paper is on intralesional agents, their evolution and efficacy of treatments. The mere fact that so many agents have been tried is a testament to the incomplete knowledge that we have with regards to the underlying pathophysiology of the disease. Currently, the only U.S. Food and Drug Administration (FDA) approved agent that has shown fairly consistent results is Clostridium histiolyticum collagenase (XiaflexTM), whereas calcium channel blockers and interferons (IFN) remain as off-label options.},
issn = {2223-4691}, url = {https://tau.amegroups.org/article/view/9665}
}